clopidogrel [Design Issues]

posted by velupharm – 2007-03-30 18:58 (7022 d 17:56 ago) – Posting: # 606
Views: 12,087

Dear all
we are developing clopidogrel formulation.
As far as the European regulatory point of view, can we prove BE only with its inactive metabolite, as clopidogrel itself becomes BLQ after 2hrs post dose (As Per SmPC)?

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
109 visitors (0 registered, 109 guests [including 15 identified bots]).
Forum time: 12:55 CEST (Europe/Vienna)

Science is simply common sense at its best that is,
rigidly accurate in observation, and
merciless to fallacy in logic.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5